<DOC>
	<DOCNO>NCT00634192</DOCNO>
	<brief_summary>This study design provide data pharmacokinetics ( PK ) , safety tolerability two continuous treatment regime tobramycin nebulized solution deliver via 'soft mist ' nebulizer Cystic Fibrosis ( CF ) subject . Each treatment period last 8 week . Additionally PK patient normal forced expiratory flow 1 second ( FEV1 ) ( FEV1≥80 % predict ) compare patient abnormal FEV1 ( FEV1 &lt; 80 % predict ) .</brief_summary>
	<brief_title>Pharmacokinetic Evaluation 8 -Week Treatment With Inhaled Tobramycin</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Male female subject age ≥6 year time screening , Informed Consent Form sign patient appropriate parent/legal guardian , prior studyrelated procedure . Confirmed diagnosis CF presence one clinical feature CF addition quantitative pilocarpine iontophoresis sweat chloride test &gt; 60 mEq/L ; identification wellcharacterized diseasecausing mutation CFTR gene ; abnormal nasal transepithelial potential difference characteristic CF . P aeruginosa must present sputum deep throat swab ( bronchoalveolar lavage [ BAL ] ) screen visit within 6 month prior screen . History sputum ( BAL ) culture yield Burkholderia cepacia ( B cepacia ) within 2 year prior screen and/or sputum culture yield B cepacia screening . FEV1 &lt; 25 % normal predict value age , sex , height base Knudson criterion screen . Hemoptysis 60 cc time within 30 day prior study drug administration . Known local systemic hypersensitivity aminoglycosides inhale antibiotic . GFR &lt; 60ml/min/1.73m2 calculated Formula Schwartz , BUN 40 mg/dl , abnormal urinalysis define 2+ great proteinuria . History tinnitus pathologic audiometry diagnosis Allergic bronchopulmonary aspergillosis ( ABPA ) screen Initiation treatment macrolide antibiotic within 28 day prior study drug administration ( subject may take macrolide antibiotic time enrollment , must initiate treatment least 28 day prior study drug administration ) . Use loop diuretic within 7 day prior study drug administration . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic infection P. aeruginosa Cystic Fibrosis subject</keyword>
</DOC>